Enhancer of zeste homologue 2 (EZH2) expression in synovial sarcomas as a promising indicator of prognosis


YALÇINKAYA Ü. , UĞRAŞ N. , ÖZGÜN G., OCAKOĞLU G. , DELİGÖNÜL A. , ÇETİNTAŞ S. , ...More

BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES, vol.17, no.4, pp.302-308, 2017 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 17 Issue: 4
  • Publication Date: 2017
  • Doi Number: 10.17305/bjbms.2017.1938
  • Title of Journal : BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES
  • Page Numbers: pp.302-308
  • Keywords: Enhancer of zeste homologue 2 (EZH2), immunohistochemistry, prognostic factors, synovial sarcoma, survival analysis, SSX-FUSION-TYPE, RETROSPECTIVE ANALYSIS, SOFT-TISSUE, CANCER, MULTICENTER, CHILDREN, RISK, PROLIFERATION, ADOLESCENTS, PROGRESSION

Abstract

Synovial sarcoma (SS) is a type of soft-tissue sarcoma, often linked to poor survival. Although overexpression of enhancer of zeste homologue 2 (EZH2) has been associated with poor prognosis in different tumors, a few studies investigated this link in SS. Here, we analyzed the relationship between EZH2 expression and prognostic factors in SS. We included 29 patients with SS. Immunostaining of EZH2 was performed with (D2C9) XP (TM) Rabbit mAb antibody, and the results were classified as low EZH2 expression (negative or weak expression) and high EZH2 expression category (moderate or strong expression). Analysis of survival in relation to prognostic factors was performed with Kaplan-Meier survival curves and Cox proportional hazard regression analysis. Our sample included 19/29 female and 10/29 male patients, with age range 16-63 years. The tumor diameter ranged from 2 to 15 cm. Necrosis was observed in 15/29 cases. Sixteen cases had > 10 mitoses per 50 high-power fields (HPFs). Out of 29 cases, 14 showed low and 15 had high EZH(2) expression. Statistically significant results were obtained for the association between the presence of metastasis and necrosis (p = 0.042), high EZH2 expression and distant metastasis (p = 0.018), high EZH2 expression and necrosis (p = 0.016), and high EZH2 expression and the tumor size > 5 cm versus tumor size <= 5 cm (p = 0.014). Patients with all of the following: the tumor size <= 5 cm, low EZH2 expression, and without necrosis and distant metastasis had significantly longer survival time. Our results are consistent with previous studies, suggesting that EZH(2) overexpression is an indicator of poor prognosis in SS.